Bharat Immunologicals and Biologicals Corporation Ltd
BIBCLBharat Immunologicals and Biologicals Corporation Ltd
BIBCL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹111 cr, stock is ranked 2,992
High RiskStock is 3.85x as volatile as Nifty
24.972.04% (-0.52)
24.972.04% (-0.52)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -6.18 | 1.27 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bharat Immunologicals and Biologicals Corporation Limited is a biotechnology company that manufactures and produces a range of pharmaceuticals products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
PE Ratio
45.35
1Y Return
46.42%
Buy Reco %
80.00
Cipla Ltd
PE Ratio
28.51
1Y Return
18.82%
Buy Reco %
70.97
Torrent Pharmaceuticals Ltd
PE Ratio
68.45
1Y Return
60.06%
Buy Reco %
74.07
Mankind Pharma Ltd
PE Ratio
55.85
1Y Return
42.65%
Buy Reco %
80.00
Dr Reddy's Laboratories Ltd
PE Ratio
18.52
1Y Return
11.22%
Buy Reco %
34.38
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 146.95 | 129.42 | 125.37 | 36.19 | 87.87 | 68.02 | 87.01 | 79.49 | 47.41 | 8.51 | ||||||||||
Raw Materials | 114.44 | 112.93 | 70.72 | 26.97 | 92.79 | 74.30 | 67.74 | 64.93 | 35.71 | 25.40 | ||||||||||
| Power & Fuel Cost | 2.21 | 2.23 | 1.66 | 1.24 | 1.74 | 1.85 | 1.55 | 1.69 | 1.35 | |||||||||||
| Employee Cost | 9.61 | 10.03 | 10.21 | 10.31 | 9.78 | 11.37 | 14.44 | 13.85 | 15.32 | |||||||||||
| Selling & Administrative Expenses | 2.20 | 2.42 | 8.81 | 0.96 | 0.45 | 0.65 | 0.60 | 0.73 | 1.05 | |||||||||||
| Operating & Other expenses | 14.35 | 4.44 | 19.96 | 3.24 | -11.79 | -10.94 | 21.87 | 2.16 | 9.64 | |||||||||||
EBITDA | 4.14 | -2.63 | 14.01 | -6.53 | -5.10 | -9.21 | -19.19 | -3.87 | -15.66 | -16.89 | ||||||||||
| Depreciation/Amortization | 0.91 | 0.65 | 0.58 | 0.41 | 0.28 | 0.24 | 0.24 | 0.21 | 0.15 | 0.19 | ||||||||||
| PBIT | 3.23 | -3.28 | 13.43 | -6.94 | -5.38 | -9.45 | -19.43 | -4.08 | -15.81 | -17.08 | ||||||||||
| Interest & Other Items | 1.13 | 5.69 | 4.21 | 1.01 | 2.00 | 4.75 | 4.79 | 5.60 | 7.05 | 7.54 | ||||||||||
| PBT | 2.10 | -8.97 | 9.22 | -7.95 | -7.38 | -14.20 | -24.22 | -9.68 | -22.86 | -24.62 | ||||||||||
| Taxes & Other Items | 0.55 | -2.75 | 2.71 | -3.70 | -1.58 | -3.99 | -6.10 | -0.93 | -5.79 | -6.56 | ||||||||||
| Net Income | 1.55 | -6.22 | 6.51 | -4.25 | -5.80 | -10.21 | -18.12 | -8.75 | -17.07 | -18.06 | ||||||||||
| EPS | 0.36 | -1.44 | 1.51 | -0.98 | -1.34 | -2.36 | -4.20 | -2.03 | -3.95 | -4.18 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
FY 2012
Annual report
PDFFY 2013
Annual report
PDFFY 2014
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bharat Immunologicals and Biologicals Corporation Ltd | -6.53 | 1.27 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare BIBCL with any stock or ETFCompare BIBCL with any stock or ETF
BIBCL
Shareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BIBCL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNews & Opinions
Articles & Videos
Corporate
Bharat Immunological & Biolog.Corp. to hold board meeting
Bharat Immunological & Biolog.Corp. will hold a meeting of the Board of Directors of the Company on 16 August 2024.Powered by Capital Market - Live
4 months agoCapital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant